Insulin and its analogues and their affinities for the IGF1 receptor

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages

  Varewijck, Aimee J ^a   Janssen, Joseph A M J L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HOMODIMER; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR; SOMATOMEDIN C RECEPTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING AFFINITY; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; DIABETES MELLITUS; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MITOGENESIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW;

ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN; MITOGENS; NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 84867429597     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0026     Document Type: Review

References (64)

1. Belfiore A, Frasca F, Pandini G, Sciacca L & Vigneri R 2009 Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Reviews 30 586-623. (doi:10.1210/er.2008-0047)
2. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G & Haring HU 1998 The long-acting human insulin analog hoe-901 - characteristics of insulin signaling in comparison to asp(b10) and regular insulin. Hormone and Metabolic Research 30 123-129.
3. Bevan P 2001 Insulin signalling. Journal of Cell Science 114 1429-1430.
4. Bi RC, Dauter Z, Dodson E, Dodson G, Giordano F & Reynolds C 1984 Insulin's structure as a modified and monomeric molecule. Biopolymers 23 391-395. (doi:10.1002/bip.360230302)
5. Blakesley VA, Scrimgeour A, Esposito D & Le Roith D 1996 Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine & Growth Factor Reviews 7 153-159. (doi:10.1016/1359-6101(96)00015-9)
6. Boucher J, Tseng YH & Kahn CR 2010 Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. Journal of Biological Chemistry 285 17235-17245. (doi:10.1074/jbc.M110.118620)
7. Brugts MP 2009 IGF-I bioactivity in aging, health and disease. Doctoral Thesis 2009. Erasmus MC, University Medical Center Rotterdam, The Netherlands (ISBN: 978-90-8559-915-9).
8. Brugts MP, Ranke MB, Hofland LJ, van der Wansem K, Weber K, Frystyk J, Lamberts SW & Janssen JA 2008 Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. Journal of Clinical Endocrinology and Metabolism 93 2539-2545. (doi:10.1210/jc.2007-2454)
9. Chan SJ & Steiner DF 2000 Insulin through the ages: phylogeny of a growth promoting and metabolic regulatory hormone. American Zoologist 40 213-222. (doi:10.1668/0003-1569(2000)040[0213:ITTAPO]2.0.CO;2)
10. De Meyts S, Palsgaard J, Theede A-M, Gauguin L, Aladdin H & Whittaker J 2007 Mechanisims of insulin action. In Insulin and IGF-I Receptor Structure and Binding Mechanism. pp 1-32. Eds AR Saltiel & JE Pessin. Springer/Landes Bioscience: New York, NY, USA.
11. Denley A, Bonython ER, Booker GW, Cosgrove LJ, Forbes BE, Ward CW & Wallace JC 2004 Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Molecular Endocrinology 18 2502-2512. (doi:10.1210/me.2004- 0183)
12. Drejer K 1992 The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes/Metabolism Reviews 8 259-285. (doi:10.1002/dmr.5610080305)
13. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S & Gammeltoft S 1991 Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40 1488-1495. (doi:10.2337/diabetes.40.11.1488)
14. Dupont J & LeRoith D 2001 Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Hormone Research 55 (Suppl 2) 22-26. (doi:10.1159/000063469)
15. Eckardt K, May C, Koenen M & Eckel J 2007 IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50 2534-2543. (doi:10.1007/s00125-007-0815- 9)
16. Emdin SO, Dodson GG, Cutfield JM & Cutfield SM 1980 Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia 19 174-182. (doi:10.1007/BF00275265)
17. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A & Vigneri R 2008 The role of insulin receptors and IGF-I receptors in cancer and other diseases. Archives of Physiology and Biochemistry 114 23-37. (doi:10.1080/13813450801969715)
18. Froesch ER, Zenobi PD & Zapf J 1993 Metabolic effects of insulin-like growth factor-I and possible therapeutic aspects in diabetes. In Growth hormone and Insulin-like Growth Factor, pp 109-129. Eds A Flyvbjerg, H Ørskov & KGMM Alberti. Wiley: Chicester, West Sussex, UK.
19. Giorgino F, Belfiore A, Milazzo G, Costantino A, Maddux B, Whittaker J, Goldfine ID & Vigneri R 1991 Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Molecular Endocrinology 5 452-459. (doi:10.1210/mend-5-3-452)
20. Hansen BF 2008 Insulin analogues with increased mitogenic potency - are they safe? Hormone and Metabolic Research 40 431-433. (doi:10.1055/s-2008- 1062740)
21. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH & Lundemose AG 1996 Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochemical Journal 315 (Pt 1) 271-279.
22. Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A & Russell-Jones D 2011 Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 54 2226-2231. (doi:10.1007/s00125-011-2203-8)
23. Harada S, Smith RM & Jarett L 1999 Mechanisms of nuclear translocation of insulin. Cell Biochemistry and Biophysics 31 307-319. (doi:10.1007/BF02738245)
24. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J & Kurtzhals P 2004 The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmacological Research 21 1498-1504. (doi:10.1023/B:PHAM.0000036926.54824.37)
25. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C & Draeger E 2004 Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 1614-1620. (doi:10.2337/diabetes.53.6.1614)
26. Hennige AM, Lehmann R, Weigert C, Moeschel K, Schauble M, Metzinger E, Lammers R & Haring HU 2005 Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes 54 361-366.
27. Humbel RE 1990 Insulin-like growth factors I and II. European Journal of Biochemistry 190 445-462. (doi:10.1111/j.1432-1033.1990.tb15595.x)
28. Juul A 2003 Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Hormone & IGF Research 13 113-170. (doi:10.1016/S1096-6374(03)00038-8)
29. Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang L, Strifler BA, Li S, Shang J, Beals JM et al. 2007 pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides 28 935-948.
30. Kuerzel GU, Shukla U, Scholtz HE, Pretorius SG, Wessels DH, Venter C, Potgieter MA, Lang AM, Koose T & Bernhardt E 2003 Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Current Medical Research and Opinion 19 34-40. (doi:10.1185/030079902125001416)
31. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C & Trub T 2000 Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 999-1005. (doi:10.2337/diabetes.49.6.999)
32. LeRoith D, Adamo D, Werner H & Roberts Jr CT 1995 Molecular and cellular biology of the insulin-like growth factors. In Molecular Endocrinology, Basic Concepts and Clinical Correlations, pp 181-183. Ed BD Weintraub. Raven Press: New York, NY, USA.
33. Liefvendahl E & Arnqvist HJ 2008 Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-1. Hormone and Metabolic Research 40 369-374.
34. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K et al. 1996 Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39 281-288. (doi:10.1007/BF00418343)
35. Mayer D, Shukla A & Enzmann H 2008 Proliferative effects of insulin analogues on mammary epithelial cells. Archives of Physiology and Biochemistry 114 38-44. (doi:10.1080/13813450801900645)
36. Milazzo G, Sciacca L, Papa V, Goldfine ID & Vigneri R 1997 ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Molecular Carcinogenesis 18 19-25. (doi:10.1002/(SICI)1098-2744(199701)18:1 〈19::AID-MC3〉 3.0.CO;2-M)
37. Moller DE, Yokota A, Caro JF & Flier JS 1989 Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Molecular Endocrinology 3 1263-1269. (doi:10.1210/mend-3-8-1263)
38. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A & McClain DA 1990 Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO Journal 9 2409-2413.
39. Nagel JM, Staffa J, Renner-Muller I, Horst D, Vogeser M, Langkamp M, Hoeflich A, Goke B, Kolligs FT & Mantzoros CS 2010 Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Hormones & Cancer 1 320-330. (doi:10.1007/s12672-010-0020-z)
40. Nakagawa SH & Tager HS 1987 Role of the COOH-terminal B-chain domain in insulin-receptor interactions. Identification of perturbations involving the insulin mainchain. Journal of Biological Chemistry 262 12054-12058.
41. Nelson JD, LeBoeuf RC & Bomsztyk K 2011 Direct recruitment of insulin receptor and ERK signaling cascade to insulin-inducible gene loci. Diabetes 60 127-137. (doi:10.2337/db09-1806)
42. Nielsen FS, Jorgensen LN, Ipsen M, Voldsgaard AI & Parving HH 1995 Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38 592-598. (doi:10.1007/BF00400729)
43. Owens D BA 2000 Diabetes, current perspectives. In Designer Insulins: Have They Revolutionized Insulin Therapy?. Ed DJ Betteridge. Martin Dunitz Ltd: London, UK.
44. Owens DR & Bolli GB 2008 Beyond the era of NPH insulin - long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technology & Therapeutics 10 333-349. (doi:10.1089/dia.2008.0023)
45. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R & Belfiore A 2002 Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. Journal of Biological Chemistry 277 39684-39695. (doi:10.1074/jbc.M202766200)
46. Podlecki DA, Smith RM, Kao M, Tsai P, Huecksteadt T, Brandenburg D, Lasher RS, Jarett L & Olefsky JM 1987 Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects. Journal of Biological Chemistry 262 3362-3368.
47. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 8 915-928. (doi:10.1038/nrc2536)
48. Rinderknecht E & Humbel RE 1978 The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. Journal of Biological Chemistry 253 2769-2776.
49. Sandow J 2009 Growth effects of insulin and insulin analogues. Archives of Physiology and Biochemistry 115 72-85. (doi:10.1080/13813450902835690)
50. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S & Vigneri R 2010 Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53 1743-1753. (doi:10.1007/s00125- 010-1760-6)
51. Siddle K, Urso B, Niesler CA, Cope DL, Molina L, Surinya KH & Soos MA 2001 Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochemical Society Transactions 29 513-525. (doi:10.1042/BST0290513)
52. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL et al. 1997 Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40 (Suppl 2) S54-S61. (doi:10.1007/s001250051402)
53. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R & Tennagels N 2010 In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 5 e9540.
54. Staiger K, Hennige AM, Staiger H, Haring HU & Kellerer M 2007 Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Hormone and Metabolic Research 39 65-67. (doi:10.1055/s-2007-957352)
55. Stammberger I, Seipke G & Bartels T 2006 Insulin glulisine - a comprehensive preclinical evaluation. International Journal of Toxicology 25 25-33. (doi:10.1080/10915810500488379)
56. Sussenbach JS, Steenbergh PH & Holthuizen P 1992 Structure and expression of the human insulin-like growth factor genes. Growth Regulation 2 1-9.
57. Tattersall RB 2003 The history of diabetes. In Textbook of Diabetes , pp 1.1-1.22. Eds JC Pickup, G Williams. Blackwell Science: Boston, MA, USA.
58. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A & Draeger E 2003 Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 590-596. (doi:10.2337/diacare.26.3.590)
59. Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SW, Hofland LJ & Janssen JA 2010 Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. Growth Hormone & IGF Research 20 427-431. (doi:10.1016/j.ghir.2010.10.002)
60. Varewijck AJ, Janssen JA, Vahatalo M, Hofland LJ, Lamberts SW & Yki-Jarvinen H 2012 Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia 55 1186-1194. (doi:10.1007/s00125-011-2435- 7)
61. Vigneri P, Frasca F, Sciacca L, Pandini G & Vigneri R 2009 Diabetes and cancer. Endocrine-Related Cancer 16 1103-1123. (doi:10.1677/ERC-09-0087)
62. Vigneri R, Squatrito S & Sciacca L 2010 Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetologica 47 271-278. (doi:10.1007/s00592-010-0215-3)
63. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S et al. 2006 Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 442-451. (doi:10.1007/s00125-005-0132-0)
64. Zelobowska K, Gumprecht J & Grzeszczak W 2009 Mitogenic potency of insulin glargine. Endokrynologia Polska 60 34-39.